A pill that mimics Viagra by relaxing blood vessels and increasing blood flow to the brain can slow cognitive decline in people with Alzheimer’s disease by almost a third, according to a global study. The drug, called AR1001, is a phosphodiesterase-5 (PDE5) inhibitor—the same family of medicines as Viagra—and showed promising results in a phase three trial.
Alzheimer’s is the most common form of dementia, a condition forecast to affect 153 million people worldwide by 2050. With no cure currently available, any treatment that can slow progression is eagerly awaited.
What the AR1001 Trial Found
In a stage three trial spanning 13 countries, including the UK, researchers found that AR1001 slowed decline by 31% in patients with early Alzheimer’s disease who were not receiving any other treatment. The study was presented at the Clinical Trials on Alzheimer’s Disease conference in Boston.
The drug’s manufacturer, South Korean company AriBio, reported that AR1001 slowed decline in 604 people taking no other Alzheimer’s drugs. However, in a wider group of patients who were taking other medications, the tablet did not achieve statistically significant results.
Experts not involved with the study urged caution but described the results as “exciting” and “very promising,” suggesting they could signal a “totally new treatment” for Alzheimer’s.
How AR1001 Works
AR1001 belongs to the PDE5 inhibitor class, which includes Viagra (sildenafil). These drugs work by relaxing blood vessels and improving blood flow. In the context of Alzheimer’s, increased blood flow to the brain may help support brain health and slow cognitive decline.
This mechanism is different from existing Alzheimer’s treatments, which typically target amyloid plaques or other aspects of the disease. If confirmed, AR1001 would represent a new approach to managing the condition.
Key Takeaways from the Study
- 31% slowing of decline in early Alzheimer’s patients not on other treatments.
- AR1001 is a PDE5 inhibitor, same class as Viagra, and works by improving blood flow to the brain.
- The trial spanned 13 countries and included 604 patients in the primary analysis.
- Results were not statistically significant in patients also taking other Alzheimer’s drugs.
- Experts call the findings “very promising” but urge caution until full data are published.
Expert Reactions and Caveats
Prof Tara Spires-Jones, a professor of neurodegeneration at the University of Edinburgh and a fellow at the Academy of Medical Sciences, said the results looked “very promising.” However, she and others emphasized the need for further analysis and peer review.
The fact that the drug did not show significant benefit in patients already on other treatments raises questions about how AR1001 might fit into the broader treatment landscape. It may be most effective as a standalone therapy in early-stage patients.
What This Means for Alzheimer’s Treatment
If AR1001 continues to show benefit in further analyses, it could become a new option for the millions of people with early Alzheimer’s. The drug’s safety profile is also important: PDE5 inhibitors are generally well tolerated, with side effects such as headache, flushing, and indigestion.
However, it is important to note that this is a phase three trial, and the full results have not yet been published in a peer-reviewed journal. Regulatory approval would require a thorough review of all data. The background to this story is set out in Elderly: latest articles.
Comparison of Alzheimer’s Treatment Approaches
| Treatment | Mechanism | Status | Key Findings |
|---|---|---|---|
| AR1001 | PDE5 inhibitor; improves blood flow | Phase 3 trial completed | 31% slowing in early Alzheimer’s patients not on other drugs |
| Lecanemab | Monoclonal antibody; targets amyloid | Approved (accelerated) | Slows decline by ~27% in early Alzheimer’s |
| Donepezil | Cholinesterase inhibitor | Approved | Modest symptomatic benefit |
| Memantine | NMDA receptor antagonist | Approved | Modest benefit in moderate to severe Alzheimer’s |
FAQ
What is AR1001?
AR1001 is an experimental drug being developed by AriBio for Alzheimer’s disease. It is a PDE5 inhibitor, the same class as Viagra, and works by relaxing blood vessels and increasing blood flow to the brain.
How effective is AR1001 for Alzheimer’s?
In a phase three trial, AR1001 slowed cognitive decline by 31% in patients with early Alzheimer’s who were not taking other treatments. However, it did not show statistically significant benefit in patients also on other Alzheimer’s drugs.
Is AR1001 available now?
No, AR1001 is not yet available. The phase three trial results were recently presented at a conference, and the drug must undergo regulatory review before it can be approved for public use.
What are the side effects of AR1001?
As a PDE5 inhibitor, AR1001 may cause side effects similar to Viagra, such as headache, flushing, and indigestion. However, specific side effect data from the trial have not been fully reported.